Anticoagulation in Pregnant Women with a Bileaflet Mechanical Cardiac Valve Replacement
Background. We investigated the risk and outcome of anticoagulation in pregnant women who had a mechanical valve.
Materials and Methods. This retrospective study was undertaken for 41 pregnancies (27 women, 33.1 ± 4.7 years old) from January 1990 to December 2005. Patients were divided into 3 groups: group I (n = 5) took warfarin throughout the pregnancy, group II (n = 18) took heparin throughout the pregnancy, and group III (n = 18) took heparin in the 1st trimester and warfarin from a gestational age of 12 to 20 weeks.
Results. Twenty-three pregnancies (56.1%) resulted in live births, 11 (26.8%) in stillbirths, and 8 (19.5%) in spontaneous abortions (SA). In group I, there were 2 live births (40.0%), 2 stillbirths (40.0%), and 1 SA (20.0%); in group II, there were 10 live births (55.6%), 1 stillbirth (5.6%), and 7 SA (38.9%); and in group III, there were 10 live births (55.6%), 8 stillbirths (44.4%), and no SA. No significant difference was observed between the 3 groups in terms of successful delivery rates (P = .826).
Conclusion. The probability of successful delivery was low. No single reliable anticoagulation protocol in pregnant patients with mechanical valves emerged from the collated data.
Al-Lawati AM, Venkitraman M, Al-Delaime T, Valliathu J. 2002. Pregnancy and mechanical heart valves replacement; dilemma of anticoagulation. Eur J Cardiothorac Surg22:223-7.nBerndt N, Khan I, Gallo R. 2000. A complication in anticoagulation using low-molecular weight heparin in a patient with mechanical valve prosthesis. A case report. J Heart Valve Dis9:844-6.nChan WS. 1999. What is the optimal management of pregnant women with valvular heart disease in pregnancy? Hemostasis29(suppl 1):105-6.nChan WS. 2000. Anticoagulation of pregnant women with mechanical heart valves: a systematic review. Arch Intern Med160:191-6.nChoi SH, Ko KP, Han JO, Chui JB, Kim GH. 2000. Anticoagulation therapy in pregnant women with mechanical cardiac valve prosthesis. Korean J Thorac Cardiovasc Surg33:502-6.nConti RC. 2003. Anticoagulation for mechanical valve prostheses during pregnancy. Clin Cardiol26:303-4.nDahlman T, Lindvall N, Hellgren M. 1990. Osteopenia in pregnancy during long-term heparin treatment: a radiological study postpartum. Br J Obstet Gynadecol97:221-8.nEdmunds Jr HL, Clark RE, Cohn LH, Grunkemeier GL, Miller DC, Weisel RD. 1996. Guidelines for reporting morbidity and mortality after cardiac valvular operations. Ann Thorac Surg62:932-5.nElkayam UR. 1996. Anticoagulation in pregnant women with prosthetic heart valves: a double jeopardy. J Am Coll Cardiol27:1704-6.nGinsberg JS, Hirsh J, Turner DC, Levine MN, Burrows R. 1989. Risks to the fetus of anticoagulant therapy during pregnancy. Thromb Haemost61:197-203.nGinsberg JS, Kowalchuk G, Hirsh J, Brill Edwards P, Burrows R. 1989. Heparin therapy during pregnancy: risks to the fetus and mother. Arch Intern Med149:2233-6.nHall JG, Pauli RM, Wilson KM. 1980. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med68:122-140.nHirsh J. 1991. Oral anticoagulant drugs. N Engl J Med324:1865-75.nIan AG. 2006. Anticoagulation in pregnancy. J Thromb Thrombolysis21:57-65.nIturbe-Alessio I, Fonseca MC, Mutchinik O, Santos MA, Zajarias A, Salazar E. 1986. Risks of anticoagulant therapy in pregnant women with artificial heart valves. N Engl J Med315:1390-93.nLee SY, Jang BC, Park HG, et al. 1999. Pregnancy in patients with prosthetic heart valve. Korean J Thorac Cardiovasc Surg32:1023-30.nLev-Ran O, Kramer A, Gurevitch J, Shapira I, Mohr R. 2000. Low- molecular-weight heparin for prosthetic heart valves: treatment failure. Ann Thorac Surg69:264-5.nNelson-Percy C, Letsky EA, de Swiet M. 1997. Low molecular weight heparin for obstetric thromboprophylaxis: experience of 69 pregnancies in 61 women at high risk. Am J Obstet Gynecol176:1062-8.nRainer GL, Stefan F, Arjang R, Axel H. 2002. Anticoagulation for prosthetic heart valves during pregnancy: is low-molecular weight heparin an alternative? Eur J Cardiothorac Surg21:577-9.nSalazar E, Iziguirre R, Verdego J, Mutchinick O. 1996. Failure of adjusted doses of subcutaneous heparin to prevent thromboembolic phenomena in pregnant patients with mechanical cardiac valve prostheses. J Am Coll Cardiol27:1698-1703.nSareli P, England MJ, Berk MR, et al. 1989. Maternal and fetal sequelae of anticoagulation during pregnancy in patients with mechanical heart valve prostheses. Am J Cardiol63:1462-5.nSbarouni E, Oakley CM. 1994. Outcome of pregnancy in women with valve prosthesis. Br Heart J71:196-201.nVitale N, De Feo M, De Santo LS, Pollice A, Tedesso N, Cotrufo M. 1999. Dose-dependent fetal complications of warfarin in pregnant women with mechanical valves. J Am Coll Cardiol33:1637-41.n
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).